Oncotech launches the first-ever mobile cancer screening tool

Oncotech's real-time cancer diagnostic tool lets you check for cancer right from your smartphone

Doctor touching a screen with reflections of medial things

Oncotech‌ ‌Nordic‌ ‌AB has developed a mobile cancer diagnosis tool that can spot precancerous symptoms and underlying cancer-related diseases.

Dubbed Ophtascan, the real-time screening and detection system can also identify all four stages of cancer and targeted oncological diseases in the human body.

"By simply using their own smartphone devices, users can photograph their iris, and upload the image to Oncotech's server," said Oncotech.

Oncotech's artificial intelligence-powered diagnostic and deep learning system then sends the results back to the user. All of this happens in under 25 seconds.

"People will be able to self-diagnose for pre-cancerous and targeted existing cancerous conditions via a smartphone in-real time. The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists," explained Andre Rafnsson, Oncotech CEO.

Ophtascan can screen for lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer in its current version.

Ophtascan was validated last year following tests on 800 oncology patients over three years. The tool's scanning precision hit a reported 96% success rate. Rafnsson anticipates reaching a 98-99% precision scanning rate by the third quarter of 2021.

Related Resource

IT Pro 20/20: Understanding our complicated relationship with AI

The 16th issue of IT Pro 20/20 looks at the very human problems associated with artificial intelligence

IT Pro 20/20: Understanding our complicated relationship with AIDOWNLOAD NOW

Furthermore, a new study is underway to determine whether Ophtascan tests can provide early warning signs for Type 2 diabetes.

"Our patent is now pending for the software and design algorithms. We have diligently started discussions with several telemedicine and remote health diagnostic business partners in Europe, North America and Asia with a view to license the Ophtascan™ technology," added Rafnsson.

"Technically advanced businesses can see the potential impact of this breakthrough in increased positive medical outcomes for patients. Many factors determine cancer survival rate, and early detection is one of the most significant determinants. Ophtascan ™ is precise, quick, well documented and is highly cost-effective."

Featured Resources

How virtual desktop infrastructure enables digital transformation

Challenges and benefits of VDI

Free download

The Okta digital trust index

Exploring the human edge of trust

Free download

Optimising workload placement in your hybrid cloud

Deliver increased IT agility with the cloud

Free Download

Modernise endpoint protection and leave your legacy challenges behind

The risk of keeping your legacy endpoint security tools

Download now

Recommended

Industry "delighted" with UK's 'landmark' anti-bias AI standard
artificial intelligence (AI)

Industry "delighted" with UK's 'landmark' anti-bias AI standard

30 Nov 2021
Sophos Intercept X Advanced review: AI-powered protection
endpoint security

Sophos Intercept X Advanced review: AI-powered protection

30 Nov 2021
Vast majority of US healthcare web apps vulnerable to attack
network security

Vast majority of US healthcare web apps vulnerable to attack

24 Nov 2021
RateGain’s new SaaS simplifies hotel content management
software as a service (SaaS)

RateGain’s new SaaS simplifies hotel content management

12 Nov 2021

Most Popular

Sony pulls out of MWC 2022
Business operations

Sony pulls out of MWC 2022

14 Jan 2022
How to boot Windows 11 in Safe Mode
Microsoft Windows

How to boot Windows 11 in Safe Mode

6 Jan 2022
Dell XPS 15 (2021) review: The best just got better
Laptops

Dell XPS 15 (2021) review: The best just got better

14 Jan 2022